AMANDA SPENCE: Open Payments
NPI 1437624087 · NEW BRITAIN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,057 in 163 payments from 31 companies in 2025. Trend: 2023 $2,022 · 2024 $2,696 · 2025 $3,057
Food & beverage: $3,037Education: $20
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 63 | $890 |
| Neurocrine BioSciences, Inc. | 10 | $186 |
| Lilly USA, LLC | 7 | $168 |
| Amgen Inc. | 7 | $154 |
| Exact Sciences Corporation | 8 | $151 |
| PFIZER INC. | 11 | $137 |
| Axsome Therapeutics, Inc. | 4 | $130 |
| Amneal Pharmaceuticals LLC | 6 | $129 |
| Phathom Pharmaceuticals, Inc. | 4 | $102 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $89 |
Products named: VRAYLAR, UBRELVY, INGREZZA, Auvelity, UNITHROID, EVENITY, VOQUEZNA, The Cologuard Plus Collection Kit.
Industry payments across CT — which companies pay providers there.
